



Press Release 18 September 2013

Medivir Capital Markets Day on 10 October 2013

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced that a Capital Markets Day will be arranged for journalists, analysts and investors, on Thursday 10 October, in Stockholm.

Time: Thursday 10 October, at 2-5 pm CEST

Venue: Conference Center Strandvägen 7A, Stockholm

Invitation for: Media, analysts and institutional investors

The meeting will be hosted by CEO Maris Hartmanis who will update on Medivir's current operations, its marketed products as well as the R&D projects. A more detailed program will be distributed the week before the meeting.

Other participants will include Richard Bethell (EVP Discovery Research), Charlotte Edenius (EVP Development), Birgitta Erlandson (Business Unit Director), Anders Kärnell (Medical Director), Henrik Krook (EVP Commercial) and Rein Piir (EVP Corporate Affairs & IR).

The event will also be available via Webcast accessible through Medivir's website; www.medivir.com, under the heading "IR/Latest events", as of 10 October from 6 pm CEST.

Registration for journalists, analysts and investors

To participate, please register at; enter@medivir.se, or by phone to +46 8 407 64 82, no later than 7 October.

For more information please contact:

Rein Piir, EVP Corporate Affairs & IR

Mobile: +46 708 537 292.

About Medivir

Medivir is an emerging research-based pharmaceutical company focused on infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company's key pipeline asset is simeprevir, a novel protease inhibitor in registration phase for hepatitis C that is being developed in collaboration with Janssen R&D Ireland. Medivir has also a broad product portfolio with prescription pharmaceuticals in the Nordics.

For more information about Medivir AB, please visit the Company's website: www.medivir.com

Medivir is a collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C. We are passionate and uncompromising in our mission to develop and commercialize innovative pharmaceuticals that improve people's health and quality of life.